Others showed that lymphocyte infusions (CD3+, CD3+/HLA-DR+, CD4+, and CD8+) lowered recurrence and improved recurrence-free outcomes after surgery in HCC patients [94]; CIK therapy improved overall survival in HCC patients [95]; and infusion of CD3+/CD56+ and CD3+/CD56− T cells, as well as CD3−/CD56+ NKT cells increased recurrence-free and overall survival in HCC patients who underwent surgical resection or RFA or percutaneous ethanol injection [96]. The gene discussed is NCAM1; the disease is hepatocellular carcinoma.